ACHE and Alzheimer disease: Compared with AChE, butyrylcholinesterase (BChE) plays a supportive role in cholinergic neurotransmission, but its level and activity significantly increase in the late stage of AD, so it is considered to be a promising drug target, therefore, the selective-BChE or dual ChE inhibitors may be more effective for advanced AD patients3,4.